Skip to main content
Show them a world beyond PNH.

Start with FABHALTA—a groundbreaking PNH treatment

Groundbreaking hemoglobin (Hb) improvements with the first and only FDA-approved oral monotherapy for adults with PNH. Primary end points (FABHALTA vs C5 inhibitors [C5is: eculizumab and ravulizumab]): response rates for sustained Hb increase of ≥2 g/dL: 82.3% (N=62) vs 0% (N=35) with C5is (difference: 81.5; 95% CI, 71.6-91.4; P<0.0001). Response rates for sustained Hb of ≥12 g/dL: 67.7% (N=62) vs 0% (N=35) with C5is (difference: 66.6; 95% CI, 54.6-78.6; P<0.0001). Both end points were measured in the absence of red blood cell transfusions after 24 weeks. Differences reflect an adjusted difference in proportion.1    
Learn more about FABHALTA data in C5i-experienced patients

FABHALTA is an FDA-approved treatment for adults with PNH. FABHALTA has displayed efficacy in C5i-experienced and complement inhibitor–naive patients with PNH.1 

FABHALTA (Fab-HALT-ah) describes a Factor B inhibitor (FAB) of the alternative pathway (ALTA) of the complement system.1

C5i, C5 inhibitor; Hb, hemoglobin; PNH, paroxysmal nocturnal hemoglobinuria. 

1. Fabhalta. Prescribing information. Novartis Pharmaceuticals Corp.